Teva Pharma (TEVA) Is Said To Explore Options For Bowel Inflammation Drug - Bloomberg
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $7.28 +0.69%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 2.1%
EPS Growth %: -22.1%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 2.1%
EPS Growth %: -22.1%
Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Teva Pharma (NYSE: TEVA) Is Said To Explore Options For Bowel Inflammation Drug - Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
- Needham & Company Reiterates Buy Rating on Apple (AAPL); 'AAPL Needs to Buy DIS to Drive Adoption of Vision Pro'
- Elon Musk's Neuralink valued at about $5 billion - Reuters
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
